DON is a glutamine antagonist that extensively inhibits glutamine metabolism and inactivates a variety of glutamine-metabolizing enzymes by competing for covalent binding to the active site of glutamine [73]
The extensive SURPASS clinical trial programme and MHRA-approved prescribing information do not identify thrombotic events as a recognised side effect of tirzepatide
Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I
The practical feasibility of accurate split dosing depends on having the right tools and the right formulation
Carlos Sanchez HealthyMe Founder Glucagon-like peptide-1 (GLP-1) therapies are a revolutionary class of medications that mimic a natural hormone to regulate blood sugar and appetite
Providing better support, especially in the initial phase of treatments such as GLP-1s, can greatly improve the user experience, reduce anxiety and help users adhere to their treatment plans